The SELECT trial showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease, without requiring a diabetes diagnosis. The FLOW trial showed kidney benefits with semaglutide use in patients with type 2 diabetes and chronic kidney disease. Improvements in hard clinical outcomes like cardiac events, kidney disease, and death are commonly observed with GLP-1 use, and are due to both the direct effects of treating the obesity, and indirect effects of the medications themselves
All that a dermatotrichologist needs to know about hair camouflage: a comprehensive review
It was a pre-approval cardiac safety assessment trial with a primary objective of non-inferiority to placebo, which was basically done to get early approval as per regulatory guidance
Adding the Precision Peptide Genetic Test after your first month helps personalize your therapywhether you stay with semaglutide, switch to tirzepatide, or explore combination options like GLP-Squaredbased on your unique peptide-pathway genetics
Specifications First available: 03/2025 Shipping weight: 1.17 lb Product code: MTB-80010 UPC: 764779800109 Package quantity: 16 fl oz Dimensions: 8.6 x 2.5 x 2.45 in , 1.17 lb Suggested use As a dietary supplement, for optimal results, take 1 tablespoon (or the equivalent of 1/2 a capful) of liquid L-Carnitine 3500, from 1 to 3x daily
